51,822 Johnson & Johnson $JNJ Shares Bought by Sapient Capital LLC

Sapient Capital LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 104.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 101,237 shares of the company’s stock after buying an additional 51,822 shares during the period. Sapient Capital LLC’s holdings in Johnson & Johnson were worth $26,801,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in JNJ. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares during the last quarter. Deutsche Bank AG grew its stake in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Johnson & Johnson by 8.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock valued at $3,575,255,000 after acquiring an additional 1,376,828 shares during the last quarter. Amundi lifted its stake in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Finally, Nuveen LLC lifted its stake in Johnson & Johnson by 6.9% in the 4th quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock worth $2,195,568,000 after purchasing an additional 683,967 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong earnings setup: Analysts are focused on JNJ’s September-quarter revenue, earnings, pharmaceutical growth and operating performance. The company has a history of exceeding estimates, while its latest quarter showed 6.6% year-over-year revenue growth and adjusted EPS above consensus. JNJ’s full-year 2026 EPS outlook is $11.60-$11.75. Johnson & Johnson Q3 earnings preview
• Positive Sentiment: Pipeline could support faster growth: Positive longer-term data for ICOTYDE in psoriasis and encouraging Phase 3 multiple-myeloma results for the Tecvayli-Talvey combination strengthen the case that JNJ can generate growth beyond its traditional defensive profile. Johnson & Johnson long-term growth outlook
• Positive Sentiment: Analyst and dividend support: Guggenheim reaffirmed a Buy rating with a $287 price target, while other coverage continues to highlight JNJ’s 64-year record of dividend increases. The company is viewed as offering more dependable cash generation than higher-yielding but financially weaker peers. Johnson & Johnson dividend outlook
• Neutral Sentiment: Valuation reflects quality: Commentary comparing JNJ with Pfizer argues that JNJ commands a higher earnings multiple because its earnings outlook is more stable and potentially stronger. That premium may support the shares, but it also leaves less room for disappointment if quarterly results or guidance fall short. Johnson & Johnson valuation comparison
• Negative Sentiment: Key risks remain: Investors continue to monitor biosimilar competition, slower MedTech growth and ongoing talc litigation. These issues could pressure future pharmaceutical sales, margins or investor confidence despite the company’s dividend record. Johnson & Johnson risks and dividend analysis

Johnson & Johnson Trading Down 0.6%

Shares of NYSE JNJ traded down $1.60 during trading hours on Thursday, hitting $256.85. 6,146,800 shares of the company traded hands, compared to its average volume of 7,971,840. The stock has a market capitalization of $618.99 billion, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21. The company’s 50 day moving average price is $265.73 and its 200 day moving average price is $248.93. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.

Insiders Place Their Bets

In other news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Morgan Stanley upped their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Tuesday, September 29th. Finally, Bank of America reaffirmed a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $276.22.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.